|Articles|October 1, 2003

October 2003
Volume 9
Issue 10

Impact of Maine's Medicaid Drug Formulary Change on Non-Medicaid Markets: Spillover Effects of a Restrictive Drug Formulary

Author(s)Y. Richard Wang, MD, PhD, Mark V. Pauly, PhD, Y. Aileen Lin, MS

Download PDF: Impact of Maine's Medicaid Drug Formulary Change on Non-Medicaid Markets: Spillover Effects of a Restrictive Drug Formulary

Articles in this issue

over 22 years ago

Article

The Ripple Effects of a Restrictive Medicaid Formulary

over 22 years ago

Article

Smoking Status Identification: Two Managed Care Organizations' Experiences With a Pilot Project to Implement Identification Systems in Independent Practice Associations

over 22 years ago

Article

A Clinical Decision and Economic Analysis Model of Cancer Pain Management

over 22 years ago

Article

Barriers to Mental Health Referral From Pediatric Primary Care Settings

over 22 years ago

Article

Better Bone Density Reporting: T-score Report Versus Fracture Risk Report With Outcome Analysis

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Impact of Maine's Medicaid Drug Formulary Change on Non-Medicaid Markets: Spillover Effects of a Restrictive Drug Formulary

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis